Literature DB >> 28741461

The Enzymatic Degradation of Heparan Sulfate.

Laura S Griffin1, Tracey M Gloster1.   

Abstract

Glycosaminoglycans (GAGs) such as heparan sulfate (HS) interact with a number of factors in the extracellular matrix (ECM) and as a consequence play a key role in the metabolic processes occurring within the cell. The dynamic synthesis and degradation of HS (and all GAGs) are necessary for ensuring that optimal chains are present for these functions. The degradation of HS begins at the cell surface and finishes in the lysosome, after which components can be recycled. Deficiencies or mutations in the lysosomal enzymes that process GAGs result in rare Mucopolysaccharidoses disorders (MPSs). There are few treatments available for these genetically inherited diseases and those that are available often do not treat the neurological symptoms of the disease. In this review, we discuss the enzymes involved in the degradation of HS and their related diseases, with emphasis on those located in the lysosome. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Glycosaminoglycan; degradation; enzymes; heparan sulfate; lysosome; mucopolysaccharidoses

Mesh:

Substances:

Year:  2017        PMID: 28741461     DOI: 10.2174/0929866524666170724113452

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  6 in total

1.  Mobility shift-based electrophoresis coupled with fluorescent detection enables real-time enzyme analysis of carbohydrate sulfatase activity.

Authors:  Dominic P Byrne; James A London; Patrick A Eyers; Edwin A Yates; Alan Cartmell
Journal:  Biochem J       Date:  2021-02-26       Impact factor: 3.857

Review 2.  Heparan Sulfate, Mucopolysaccharidosis IIIB and Sulfur Metabolism Disorders.

Authors:  Marta Kaczor-Kamińska; Kamil Kamiński; Maria Wróbel
Journal:  Antioxidants (Basel)       Date:  2022-03-30

Review 3.  Endothelial Glycocalyx Degradation in Critical Illness and Injury.

Authors:  Eric K Patterson; Gediminas Cepinskas; Douglas D Fraser
Journal:  Front Med (Lausanne)       Date:  2022-07-08

4.  Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo.

Authors:  Casper de Boer; Zachary Armstrong; Vincent A J Lit; Uri Barash; Gijs Ruijgrok; Ilanit Boyango; Merle M Weitzenberg; Sybrin P Schröder; Alexi J C Sarris; Nico J Meeuwenoord; Pedro Bule; Yasmine Kayal; Neta Ilan; Jeroen D C Codée; Israel Vlodavsky; Herman S Overkleeft; Gideon J Davies; Liang Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-26       Impact factor: 12.779

5.  Heparan Sulfate Biosynthetic System Is Inhibited in Human Glioma Due to EXT1/2 and HS6ST1/2 Down-Regulation.

Authors:  Victor S Ushakov; Alexandra Y Tsidulko; Gabin de La Bourdonnaye; Galina M Kazanskaya; Alexander M Volkov; Roman S Kiselev; Vyacheslav V Kobozev; Diana V Kostromskaya; Alexey S Gaytan; Alexei L Krivoshapkin; Svetlana V Aidagulova; Elvira V Grigorieva
Journal:  Int J Mol Sci       Date:  2017-11-01       Impact factor: 5.923

Review 6.  Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches.

Authors:  Noelia Benetó; Lluïsa Vilageliu; Daniel Grinberg; Isaac Canals
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.